Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
Learning Objectives
- Pulmonary arterial hypertension as a clinical condition
- Applying proteomics to risk stratification
- Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition
Christopher Rhodes, MA, Cantab, PhD
Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London
Martin R. Wilkins
Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins
More webinars
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.